Nimenrix is indicated for active immunization of individuals from 6 weeks of age against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.